WALTHAM, Mass.--( BUSINESS WIRE)-- ImmunoGen, Inc.(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться